Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.39 |
| ▸ | RXRA | P19793 | 10/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470903 | 0.78 | NR1H2 (0.44) | NR1H2NR1H3RXRALOXL2KCNH2 | |
| SCHEMBL3470923 | 0.77 | NR1H2 (0.54) | NR1H2NR1H3RXRALOXL2KCNH2 | |
| SCHEMBL3472473 | 0.71 | NR1H2 (0.55) | NR1H2NR1H3RXRALOXL2KCNH2 | |
| SCHEMBL14622606 | 0.70 | NR1H2 (0.49) | NR1H2NR1H3RXRA | |
| SCHEMBL14623327 | 0.68 | NR1H2 (0.45) | NR1H2NR1H3RXRALOXL2CNR1 | |
| SCHEMBL3472604 | 0.68 | NR1H2 (0.70) | NR1H2NR1H3RXRALOXL2KCNH2 | |
| SCHEMBL15641675 | 0.67 | NR1H2 (0.51) | NR1H2NR1H3RXRALOXL2SYK | |
| SCHEMBL3474363 | 0.67 | NR1H2 (0.44) | NR1H2NR1H3RXRASYKCYP2C9 | |
| SCHEMBL3470763 | 0.66 | NR1H2 (0.44) | NR1H2NR1H3RXRALOXL2PIK3CA | |
| SCHEMBL3471513 | 0.66 | NR1H2 (0.52) | NR1H2NR1H3RXRACNR1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |